Health Care

Filter By:

Type

Fellow

Research Team

Use comma-separated ID numbers for each author

Support the Hoover Institution

Join the Hoover Institution's community of supporters in advancing ideas defining a free society.

Support Hoover

Blank Section (Placeholder)Featured

The Libertarian: The Future Of Obamacare

via Defining Ideas (Hoover Institution)
Thursday, February 15, 2018

A new case out of Idaho may free consumers from the law's draconian regulations.

In the News

Medicaid: Where Do We Go From Here?

Wednesday, February 28, 2018
Hoover Institution, Washington DC

The Hoover Institution hosted "Medicaid:  Where Do We Go From Here?" on Wednesday, February 28, 2018 from 9:00am - 11:00am EST.

Event
Analysis and Commentary

How We Can Prevent The Next Killer Flu Epidemic

by Henry I. Millervia Newsweek
Tuesday, February 13, 2018

Seasonal outbreaks of flu kill many thousands of Americans even in a good year, and this is a bad one.

Analysis and Commentary

Personalized Medicine Needs Enlightened Regulation To Realize Its Potential

by Henry I. Millervia Journal of Commercial Biotechnology
Tuesday, February 13, 2018

[Subscription Required] Precision, or personalized, medicine, reflects that treatments -- especially those using biopharmaceuticals -- are gradually shifting from a relatively imprecise “one size fits all” approach to a more personalized one, so that patients can be matched to the best therapy based on their genetic makeup and other predictive factors. However, for the pharmaceutical industry, it could be a double-edged sword. On the one hand, it could diminish the number of patients required to demonstrate efficacy in clinical trials, but on the other, it might narrow the approved labeling indications (uses), once the FDA allows the drug to be marketed. Moreover, if regulators require huge safety studies, that could offset the advantage of being able to show efficacy with smaller numbers of patients.

Featured

Republicans Need A Nudge To Lower Health Care Costs

by Lanhee J. Chen, James C. Caprettavia The New York Times
Monday, February 12, 2018

Republicans in Congress and the Trump administration repealed the penalties associated with the Affordable Care Act’s individual mandate in the tax act that passed in December. Now they need to replace the mandate with something that will address rising premiums and command broader support. Automatic enrollment into health insurance plans is a good place to start.

Interviews

Henry Miller On The John Batchelor Show

interview with Henry I. Millervia The John Batchelor Show
Wednesday, February 7, 2018

Hoover Institution fellow Henry Miller discusses his Fox News article "Physician: We need a universal flu vaccine -- No more excuses."

In the News

Can New Bipartisan Group Break Through Divisions And Build Reform Consensus?

mentioning Lanhee J. Chenvia Modern Healthcare
Tuesday, February 6, 2018

American health policy is stuck in a deep political rut. Now a bipartisan group of prominent healthcare, political and not-for-profit leaders have come together to try to build a public consensus for how to reform the system.

Featured

Physician: We Need A Universal Flu Vaccine -- No More Excuses

by Henry I. Millervia Fox News
Tuesday, February 6, 2018

My late father could recall as a child the horrendous flu pandemic of 1918-19. Horse-drawn wagons piled with corpses rolled through the streets of Philadelphia, where the death toll that winter was 15,556. In total, more than 500,000 Americans died. Worldwide, the pandemic was the worst in history, claiming between 50 million and 100 million lives.

Analysis and Commentary

Biotechnology Can Address The Mystery And Urgency Of Alzheimer’s Disease

by Mina Marmor, Henry I. Millervia Journal Of Commercial Biotechnology
Friday, February 2, 2018

[Subscription Required] Alzheimer’s disease (AD), a scourge that in time could virtually bankrupt healthcare systems worldwide, is one of the most intensively researched areas of medicine. Because of the existing uncertainty about its pathophysiology the unavailablity of reliable diagnostic tests, it is difficult to predict which prophylactic or therapeutic interventions are likely to be effective, but many biotechnology-derived drugs are prime candidates. We summarize the most promising approaches and drugs.

Analysis and Commentary

Government Innumeracy

by David R. Hendersonvia EconLog
Thursday, February 1, 2018

This week we've seen a striking example of government innumeracy that has a good chance of badly affecting government policy.

Pages

Health Care Policy Working Group


The Working Group on Health Care Policy devises public policies that enable more Americans to get better value for their health care dollar and foster appropriate innovations that will extend and improve life.